Codex DNA Inc
NASDAQ:DNAY
P/E
Price to Earnings
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
Market Cap | P/E | ||||
---|---|---|---|---|---|
US |
C
|
Codex DNA Inc
NASDAQ:DNAY
|
59.8m USD | -1.2 | |
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
226.2B USD | 37.5 | ||
US |
Danaher Corp
NYSE:DHR
|
198.6B USD | 24.6 | ||
US |
Agilent Technologies Inc
NYSE:A
|
45.1B USD | 36.5 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
41.2B USD | 30.3 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.3T KRW | 61.8 | ||
CH |
Lonza Group AG
SIX:LONN
|
36.9B CHF | 56.4 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
32.1B USD | 41.3 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
26.1B USD | 38.3 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
24.7B USD | 43.4 | ||
US |
Waters Corp
NYSE:WAT
|
20.8B USD | 34.5 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.